Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CNVVY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CNVVY and 80,000+ other tickers.
See exactly how CNVVY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CNVVY and 80,000+ other tickers.
ConvaTec Group Plc operates as a global medical technology enterprise, specializing in the development, manufacturing, and distribution of a wide range of healthcare products. The company offers advanced wound care and skin protection solutions, tailored for the effective management of both acute and chronic wounds arising from diverse conditions such as diabetes, immobility, venous disease, traumatic injuries, burns, or complications following surgery. Furthermore, ConvaTec provides comprehensive ostomy care, including specialized devices, accessories, and support services for individuals…
Convatec Group PLC (CNVVY) Q2 2026 Earnings Call Transcript
ConvaTec Group LON: CTEC said it remained on track to meet its 2026 financial targets after reporting 5% organic revenue growth in the first half, excluding the impact of its InnovaMatrix skin-substitute product.
British medical products maker Convatec on Tuesday forecast its second-half operating margin to be materially higher than the first half, and pointed to accelerating demand for its infusion care products.
Convatec Group PLC (CNVVY) ConvaTec Group PLC, 4 Months Period Ending/ Trading Statement Call Transcript
British medical products maker Convatec on Thursday posted slower organic revenue growth for the first four months of 2026 and its CEO warned of higher costs in 2027 due to the Iran conflict, sending shares 8% lower.